P/E Ratio (TTM)
-2350.89
Regencell Bioscience Holdings Limited currently has a P/E ratio of -2350.89. The P/E ratio is a primary valuation multiple used to determine if a stock is overvalued or undervalued relative to its earnings.
Quarterly P/E
| Quarter | P/E Ratio |
|---|---|
| 2019-12-30 | -38252979.71 |
| 2020-06-30 | -22163637.64 |
| 2020-12-30 | -34147276.60 |
| 2021-06-30 | -11254835.14 |
| 2021-12-30 | -2019.13 |
| 2022-06-30 | -1883.69 |
| 2022-12-30 | -2297.11 |
| 2023-06-30 | -2804.21 |
| 2023-12-30 | -7178293.85 |
| 2024-06-30 | -6640440.30 |
| 2024-12-29 | -105.30 |
| 2025-06-30 | -1217.22 |
Annual P/E
| Year | P/E Ratio |
|---|
* P/E ratios are calculated using trailing twelve-month (TTM) earnings. Extreme values may indicate earnings anomalies or cyclical volatility.